Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON24419
NL-OMON24419
Not yet recruiting
Not Applicable

Molecular Imaging with Fluor-18 PSMA-1007 PET/CT for lymph Node sTaging in primary prostate cancer

Canisius Wilhelmina ZiekenhuisWeg door Jonkerbos 1006532 SZ NijmegenThe Netherlands0 sites100 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Canisius Wilhelmina ZiekenhuisWeg door Jonkerbos 1006532 SZ NijmegenThe Netherlands
Enrollment
100
Status
Not yet recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

ot applicable

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational non invasive

Investigators

Sponsor
Canisius Wilhelmina ZiekenhuisWeg door Jonkerbos 1006532 SZ NijmegenThe Netherlands

Eligibility Criteria

Inclusion Criteria

  • •1\.Biopsy proven adenocarcinoma of the prostate;
  • •2\.Indication for (super)extended pelvic lymph node dissection (PLND \- with or without robot\-assisted laparoscopic prostatectomy);

Exclusion Criteria

  • •1\.History of prior diagnosed or treated PCa.
  • •2\.Known concomitant malignancies (except Basal Cell Carcinoma of the skin).

Outcomes

Primary Outcomes

Not specified

Similar Trials

Terminated
Phase 2
A Study of [18]F-PSMA-1007 in Patients With Known or Suspected Metastatic Prostate CancerOncologyProstate Cancer
NCT05712174AHS Cancer Control Alberta176
Completed
Phase 1
Positron emission tomography using a newly-developed PET probe: [18F] Fluoroacetate (FACE) - human volunteer studyhealthy volunteer
JPRN-UMIN000007575Shiga Medical Center Research Institute4
Withdrawn
Not Applicable
Study of 18F-FEC for Positron Emission Tomography-Computed Tomography (PET-CT) Imaging of GBMAstrocytoma, Grade IVGiant Cell GlioblastomaGlioblastoma Multiforme
NCT00943462Centre hospitalier de l'Université de Montréal (CHUM)
Completed
Phase 3
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate CancerProstate CancerProstate Cancer Recurrent
NCT04742361ABX advanced biochemical compounds GmbH136
Not yet recruiting
Not Applicable
Molecular-guided PET/MRI (Positron Emission Tomography/Magnetic Resonance Imaging) to target hypoxia in Glioblastoma (GBM): A Pilot Study.Glioblastoma
ACTRN12617000815369Royal Brisbane and Women's Hospital5